These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25855920)

  • 1. Effects of pioglitazone and glipizide on platelet function in patients with type 2 diabetes.
    Xiao CC; Ren A; Yang J; Ye SD; Xing XN; Li SM; Chen C; Chen RP
    Eur Rev Med Pharmacol Sci; 2015; 19(6):963-70. PubMed ID: 25855920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes.
    Basu A; Jensen MD; McCann F; Nandy D; Mukhopadhyay D; McConnell JP; Rizza RA
    Endocr Pract; 2007; 13(2):147-52. PubMed ID: 17490928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
    Perez A; Zhao Z; Jacks R; Spanheimer R
    Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus.
    Erem C; Ozbas HM; Nuhoglu I; Deger O; Civan N; Ersoz HO
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):295-302. PubMed ID: 24710641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.
    Genovese S; De Berardis G; Nicolucci A; Mannucci E; Evangelista V; Totani L; Pellegrini F; Ceriello A
    Adv Ther; 2013 Feb; 30(2):190-202. PubMed ID: 23359066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus.
    Suryadevara S; Ueno M; Tello-Montoliu A; Ferreiro JL; Desai B; Rollini F; Box LC; Zenni M; Guzman LA; Bass TA; Angiolillo DJ
    Thromb Haemost; 2012 Nov; 108(5):930-6. PubMed ID: 22782352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study).
    Xu W; Bi Y; Sun Z; Li J; Guo L; Yang T; Wu G; Shi L; Feng Z; Qiu L; Li Q; Guo X; Luo Z; Lu J; Shan Z; Yang W; Ji Q; Yan L; Li H; Yu X; Li S; Zhou Z; Lv X; Liang Z; Lin S; Zeng L; Yan J; Ji L; Weng J
    J Intern Med; 2015 Jan; 277(1):137-50. PubMed ID: 25039675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
    Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia.
    Mintz ML; Minervini G
    Curr Med Res Opin; 2014 May; 30(5):761-70. PubMed ID: 24397584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial.
    Tanaka A; Komukai S; Shibata Y; Yokoi H; Iwasaki Y; Kawasaki T; Horiuchi K; Nakao K; Ueno T; Nakashima H; Tamashiro M; Hikichi Y; Shimomura M; Tago M; Toyoda S; Inoue T; Kawaguchi A; Node K;
    Heart Vessels; 2018 Sep; 33(9):965-977. PubMed ID: 29487991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone inhibits platelet function and potentiates the effects of aspirin: a prospective observation study.
    Mongan J; Mieszczanska HZ; Smith BH; Messing SP; Phipps RP; Francis CW
    Thromb Res; 2012 Jun; 129(6):760-4. PubMed ID: 22225857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Betteridge DJ; Vergès B
    Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
    Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
    Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.
    Davidson JA; Perez A; Zhang J;
    Diabetes Obes Metab; 2006 Mar; 8(2):164-74. PubMed ID: 16448520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
    Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.